Case-Based Roundtable Meetings Spotlight: June 2022

June 27, 2022

During a Targeted Oncology case-based roundtable event, Nelson Jen An Chao, MD, discussed risk management and treatment of patients with steroid-refractory acute graft-versus-host-disease as well as chronic graft-versus-host disease.

June 26, 2022

During a Targeted Oncology case-based roundtable event, Peter Voorhees, MD, discussed therapy options and transplant eligibility for patients with multiple myeloma.

June 25, 2022

During a Targeted Oncology case-based event, Chung-Han Lee, MD, PhD, and Bradley A. McGregor, MD, discussed the case of a patient with recurrent metastatic renal cell carcinoma and that of a patient at risk of recurrence following resection.

June 24, 2022

During a Targeted Oncology case-based roundtable event, John N. Allan, MD, discussed the factors for choosing treatment for chronic lymphocytic leukemia with a Bruton tyrosine kinase inhibitor.

June 23, 2022

During a Targeted Oncology case-based roundtable event, Antoinette Wozniak, MD, discussed the results of the IMpower 133 and CASPIAN trials of new agents for treating extensive-stage small cell lung cancer.

June 22, 2022

During a Targeted Oncology case-based roundtable event, Stephen Ansell, MD, PhD, discussed the options for third-line therapy for relapsed/refractory diffuse large B-cell lymphoma.

June 22, 2022

At a live virtual event, Robert J. Motzer, MD, discussed the risk factors for classifying patients with advanced renal cell carcinoma and data from several phase 3 trials of combination regimens.

June 21, 2022

During a Targeted Oncology case-based roundtable event, Ruta D. Rao, MD, discussed the case of a patient with metastatic triple-negative breast cancer who progressed following frontline adjuvant ddAC-paclitaxel.

June 21, 2022

During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with hepatocellular cancer with a medical history of Crohn disease, cirrhosis, and variceal bleeding.

June 20, 2022

During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed with participants the results of the CASPIAN and IMpower 133 trials of new regimens for extensive-stage small cell lung cancer.

June 19, 2022

During a Targeted Oncology case-based roundtable event, Chandler Park, MD, discussed the preferred first-line treatment options including tyrosine kinase inhibitor/immunotherapy combinations for metastatic clear cell renal cell carcinoma.

June 18, 2022

During a Targeted Oncology case-based roundtable event, Binod Dhakal, MD, MS, discussed key data related to the treatment of newly diagnosed multiple myeloma.

June 17, 2022

During a Targeted Oncology case-based roundtable event, Susan O'Brien, MD, discussed the case of a 71-year-old woman newly diagnosed with chronic lymphocytic leukemia.